Heteroaromatic compounds and their use as dopamine D1 ligands

Patent metadata

Field	Value
Publication number	US-9107923-B2
Application number	US-201514638677-A
Country	US
Kind code	B2
Filing date	Mar 4, 2015
Priority date	Jun 27, 2013
Publication date	Aug 18, 2015
Grant date	Aug 18, 2015

Abstract

The present invention provides, in part, compounds of Formula I:

and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

First claim

What is claimed is:

1. A compound selected from the group consisting of:
6-{4-[(3-chloro-5-fluoropyridin-2-yl)oxy]-2-methylphenyl}-1,5-dimethylpyrimidine-2,4(1H,3H)-dione;
1,5-dimethyl-6-(2-methyl-4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)pyrimidine-2,4(1H,3H)-dione; and
6-{4-[(3-chloropyridin-2-yl)oxy]-2-methylphenyl}-1,5-dimethylpyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein…

Assignees

• Pfizer

Inventors

• Brodney Michael Aaron
• Davoren Jennifer Elizabeth
• Dounay Amy Beth
• Efremov Ivan Viktorovich
• Gray David Lawrence Firman
• Green Michael Eric
• Henderson Jaclyn Louise
• Lee Chewah
• Mente Scot Richard
• O'Neil Steven Victor
• Rogers Bruce Nelsen
• Zhang Lei

Classifications

• A61P7/12

  Human Necessities · mapped topic

• A61P3/06

  Human Necessities · mapped topic

• A61P3/10

  Human Necessities · mapped topic

• A61P9/12

  Human Necessities · mapped topic

• A61P37/02

  Human Necessities · mapped topic